Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
AAAfrican American
AAPCAAPC, a professional association for medical coding
AASKAfrican American Study of Kidney Disease and Hypertension
ACEAngiotensin-converting enzyme
ACEiAngiotensin-converting enzyme inhibitor
ACRAlbumin-to-creatinine ratio
AE, AEsAdverse event
AHFSAmerican Hospital Formulary Service
aHRAdjusted hazard ratio
AIDSAcquired immunodeficiency syndrome
AJMCThe American Journal of Managed Care
AKIAcute kidney injury
ALTAlanine aminotransferase
AMKDAPOL1-mediated kidney disease
APOL1, ApoL1Apolipoprotein L1
APOL1-HRAPOL1 high-risk genotype
APOL1-KDAPOL1 kidney disease
APOLLOAPOL1 Long-term Kidney Transplantation Outcomes Network
ARBAngiotensin II receptor blocker
ARICAtherosclerosis Risk in Communities study
ARTAntiretroviral therapy
ASNAmerican Society of Nephrology
ASOAntisense oligonucleotide
ASTAspartate aminotransferase
ATPAdenosine triphosphate
AUCArea under the concentration-time curve
AUC0-24h, AUC0-24hrArea under the concentration-time curve from 0 to 24 hours
AUC0-infArea under the concentration-time curve from time 0 to infinity
AUCtauArea under the concentration-time curve over the dosing interval
AZD2373AstraZeneca development code for an investigational subcutaneous APOL1-directed therapy
BABioavailability
BCIBayesian credible interval
BMIBody mass index
BPBlood pressure
BTDBreakthrough Therapy Designation
CARDIACoronary Artery Risk Development in Young Adults study
CASChemical Abstracts Service
CIConfidence interval
CKDChronic kidney disease
CKD-EPIChronic Kidney Disease Epidemiology Collaboration
CLss/FApparent clearance at steady state
CNI, CNIsCalcineurin inhibitor
COVANCOVID-19-associated nephropathy
COVID-19Coronavirus disease 2019
CPChild-Pugh
CRComplete remission
CRICChronic Renal Insufficiency Cohort study
CTISClinical Trials Information System (European Union)
CVCoefficient of variation
CVDCardiovascular disease
CYP3A, CYP3A4Cytochrome P450 3A, cytochrome P450 3A4
DAPA-CKDDapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease trial
DDIDrug-drug interaction
DDKTsDeceased donor kidney transplants
DRIDirect renin inhibitor
EC50Half-maximal effective concentration
ECG, ECGsElectrocardiogram
EEEthinyl estradiol
eGFREstimated glomerular filtration rate
EHRElectronic health record
EMAEuropean Medicines Agency
EREndoplasmic reticulum
ERAsEndothelin receptor antagonists
ESKDEnd-stage kidney disease
ESRDEnd-stage renal disease
EUEuropean Union
FASFull Analysis Set
FDAU.S. Food and Drug Administration
FETFisher's exact test
FFSFee-for-service
FIHFirst in human
FSGSFocal segmental glomerulosclerosis
G0APOL1 reference (non-risk) allele
G1, G2APOL1 kidney risk variant alleles
GFRGlomerular filtration rate
GLP-1Glucagon-like peptide-1
GLSMRGeometric least squares mean ratio
GMPCGeometric mean percent change
GMRGeometric mean ratio
H-ESKDHypertension-attributed end-stage kidney disease
HAARTHighly active antiretroviral therapy
HCVHepatitis C virus
HDHemodialysis
HDLHigh-density lipoprotein
HEDISHealthcare Effectiveness Data and Information Set
HIVHuman immunodeficiency virus
HIVANHIV-associated nephropathy
HRHazard ratio
HRQoL, HRQOLHealth-related quality of life
HTAHealth technology assessment
IAInterim analysis
IC50Half-maximal inhibitory concentration
ICD-10-CMInternational Classification of Diseases, Tenth Revision, Clinical Modification
ICERInstitute for Clinical and Economic Review
ICFInformed consent form
IDMCIndependent Data Monitoring Committee
IFN-γInterferon gamma
IgANImmunoglobulin A nephropathy
IgAVImmunoglobulin A vasculitis
IHDIn-center hemodialysis
INNInternational Nonproprietary Name
IQRInterquartile range
IRBInstitutional review board
IXPInaxaplin
KDIGOKidney Disease: Improving Global Outcomes
KDOCKidney Donor Outcomes Cohort study
KEDKidney Health Evaluation for Patients With Diabetes (HEDIS measure)
KRTKidney replacement therapy
LDLLow-density lipoprotein
LKDsLiving kidney donors
LNLevonorgestrel (with EE); lupus nephritis
MAMedicare Advantage
MADMultiple ascending dose
MAPMean arterial pressure
MRA, MRAsMineralocorticoid receptor antagonist
mRNAMessenger ribonucleic acid
MVPMillion Veteran Program
MZE829Maze Therapeutics development code for an investigational oral APOL1 inhibitor
NCQANational Committee for Quality Assurance
NEJMThe New England Journal of Medicine
NIHNational Institutes of Health
NKFNational Kidney Foundation
OPOsOrgan procurement organizations
OROdds ratio
PCRProtein-to-creatinine ratio
PDPharmacodynamics; peritoneal dialysis
PedsQLPediatric Quality of Life Inventory
Ph2, Ph3Phase 2, phase 3
PIPPaediatric investigation plan
PKPharmacokinetics
PMPlasma membrane
PPPYPer person per year
PRIMEPRIority MEdicines scheme (European Medicines Agency)
PROPatient-reported outcome
PROMISPatient-Reported Outcomes Measurement Information System
QoLQuality of life
QTcFQT interval corrected for heart rate by Fridericia's formula
R2Coefficient of determination
RARisk alleles
RAASRenin-angiotensin-aldosterone system
RASRenin-angiotensin system
RASiRenin-angiotensin system inhibitor
RCTsRandomized controlled trials
REMSRisk Evaluation and Mitigation Strategy
RNARibonucleic acid
RPDRare Pediatric Disease designation
RRVsRenal risk variants
RWDReal-world data
SADSingle ascending dose
SAEsSerious adverse events
SBPSystolic blood pressure
SCSubcutaneous
SDStandard deviation
SF-12, SF-3612-item and 36-item Short Form Health Surveys
SFUVSafety follow-up visit
SGLT2Sodium-glucose cotransporter-2
SGLT2iSodium-glucose cotransporter-2 inhibitor
SLESystemic lupus erythematosus
SRNSSteroid-resistant nephrotic syndrome
suPARSoluble urokinase plasminogen activator receptor
T2D, T2DMType 2 diabetes mellitus
TEAEsTreatment-emergent adverse events
TRAEsTreatment-related adverse events
TSQMTreatment Satisfaction Questionnaire for Medication
UACR, uACRUrine albumin-to-creatinine ratio
uKFUnexplained kidney failure
ULNUpper limit of normal
UPCRUrine protein-to-creatinine ratio
USUnited States
USRDSUnited States Renal Data System
VX-147Vertex Pharmaceuticals development code for inaxaplin
VX-840Vertex Pharmaceuticals development code for a second investigational APOL1 inhibitor
WHOWorld Health Organization
WTWild type